OverviewSuggest Edit

ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. Its lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. Its pipeline includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family; and ARQ 761, a Beta lapachone analog being evaluated as a promoter of NQ01-mediated programmed cancer cell necrosis. 

TypePublic
Founded1993
HQBurlington, MA, US
Websitearqule.com
Employee Ratings3.3

Latest Updates

Employees (est.) (Dec 2018)36(+13%)
Revenue (FY, 2016)$4.7 M(-58%)
Share Price (Jan 2020)$20
Cybersecurity ratingAMore

Key People/Management at ArQule

Paolo Pucci

Paolo Pucci

CEO
Patrick J. Zenner

Patrick J. Zenner

Chairman
Peter S. Lawrence

Peter S. Lawrence

President and Chief Operating Officer
Timothy C. Barabe

Timothy C. Barabe

Director
Brian Schwartz

Brian Schwartz

Chief Medical Officer
Susan L. Kelley

Susan L. Kelley

Director
Show more

ArQule Office Locations

ArQule has an office in Burlington
Burlington, MA, US (HQ)
1 Wall St
Show all (1)

ArQule Financials and Metrics

ArQule Revenue

ArQule's revenue was reported to be $4.71 m in FY, 2016 which is a 58.1% decrease from the previous period.
USD

Revenue (Q3, 2019)

208.0k

Net income (Q3, 2019)

(10.7m)

EBIT (Q3, 2019)

(11.3m)

Market capitalization (16-Jan-2020)

2.4b

Closing stock price (16-Jan-2020)

20.0

Cash (30-Sept-2019)

42.2m

EV

2.4b
ArQule's current market capitalization is $2.4 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

15.9m11.3m11.2m4.7m

Revenue growth, %

(29%)0%(58%)

General and administrative expense

13.4m13.9m12.8m12.2m9.8m7.6m7.6m10.8m

R&D expense

45.0m34.0m27.6m22.3m15.6m20.0m19.5m28.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

13.7m5.0m1.3m281.0k208.0k

General and administrative expense

3.6m3.1m3.6m3.5m3.4m3.4m3.2m3.1m3.3m3.1m3.0m3.2m2.8m1.8m2.0m1.9m1.8m2.1m1.9m1.8m2.4m2.2m3.4m4.3m3.2m3.2m

R&D expense

12.8m11.1m9.3m9.3m8.1m8.2m8.1m6.0m6.7m6.2m5.0m4.4m4.3m3.2m4.2m4.3m5.3m5.2m5.0m4.6m5.8m6.8m7.3m7.4m6.3m8.3m

Operating expense total

16.4m14.2m12.9m12.8m11.5m11.6m11.3m9.1m10.0m9.3m9.1m7.6m7.1m5.0m6.2m6.2m7.1m7.3m6.8m6.3m8.2m9.0m10.7m11.7m9.5m11.5m
USDQ2, 2011

Financial Leverage

5.3 x
Show all financial metrics

ArQule Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

ArQule Online and Social Media Presence

Embed Graph

ArQule News and Updates

Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company’s Board of Directors

* Dr. Schwartz Served as ArQule’s Chief Medical Officer and Head of Research and Development Prior to the $2.7 billion Acquisition of ArQule by Merck in February 2020 *

UPDATE 2-Merck pushes deeper into targeted cancer therapy with $2.7 bln ArQule deal

Merck & Co Inc said on Monday it would buy ArQule Inc for $2.7 billion, as it looks to tap into the drug developer's experimental blood cancer therapy that targets genetic mutations.

(ARQL) Alert: Johnson Fistel Investigates Proposed Sale of ArQule, Inc.; Is $20 a Fair Price?

SAN DIEGO, Dec. 9, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of ArQule, Inc. (NASDAQ: ARQL) breached their fiduciary duties in connection with the proposed sale of the Company to Merck & Co. On...

UPDATE 1-Merck to buy cancer drug developer ArQule for $2.7 bln in cash

Merck & Co said on Monday it would buy cancer drug developer ArQule Inc in a $2.7 billion all-cash deal, bolstering its oncology franchise with the smaller rival's lead drug that is being tested as a treatment for blood cancer.

Shares of ArQule up 100% after Merck announces $2.7 billion acquisition

Shares of ArQule up 100% after Merck announces $2.7 billion acquisition
Show more

ArQule Blogs

ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting

The post ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting appeared first on ArQule.

ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting

ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting Content Import Mon, 11/25/2019 - 07:00 ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 …

ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019

The post ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019 appeared first on ArQule.

ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies

The post ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies appeared first on ArQule.

Akash Tewari - Wolfe Research

Akash Tewari - Wolfe Research melissa.oneil@… Tue, 11/05/2019 - 15:23 Akash Tewari Wolfe Research ATewari@WolfeResearch.com

ArQule Reports Third Quarter 2019 Financial Results

The post ArQule Reports Third Quarter 2019 Financial Results appeared first on ArQule.
Show more

ArQule Frequently Asked Questions

  • When was ArQule founded?

    ArQule was founded in 1993.

  • Who are ArQule key executives?

    ArQule's key executives are Paolo Pucci, Patrick J. Zenner and Peter S. Lawrence.

  • How many employees does ArQule have?

    ArQule has 36 employees.

  • Who are ArQule competitors?

    Competitors of ArQule include Chiesi USA, Moderna and R-Pharm.

  • Where is ArQule headquarters?

    ArQule headquarters is located at 1 Wall St, Burlington.

  • Where are ArQule offices?

    ArQule has an office in Burlington.

  • How many offices does ArQule have?

    ArQule has 1 office.